Molecular Signatures in Inflammatory Skin Disease
Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin Disorders
About This Trial
This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. It will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.
Who May Be Eligible (Plain English)
Original Eligibility Criteria
View original clinical language
Treatments Being Tested
Anti-TNF
Subject receives anti-TNF antibodies open-label as per guidelines
Anti-IL12/23
Subject receives anti-IL12/23 antibodies open-label as per guidelines
Anti-IL17
Subject receives anti-IL17 antibodies open-label as per guidelines
Dupilumab
Subject receives Dupilumab open-label as per guidelines
Anti-IL23
Subject receives anti-IL23 antibodies open-label as per guidelines
Baricitinib
Subject receives Baricitinib open-label as per guidelines
Abrocitinib
Subject receives Abrocitinib open-label as per guidelines
Upadacitinib
Subject receives Upadacitinib open-label as per guidelines
Tralokinumab
Subject receives Tralokinumab open-label as per guidelines
Lebrikizumab
Subject receives Lebrikizumab open-label as per guidelines
Nemolizumab
Subject receives Nemolizumab open-label as per guidelines